Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.40 |
| ▸ | BAX | Q07812 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694728 | 0.89 | LTA4H (0.50) | LTA4HNR1H2NR1H3PDK2MAPK14 | |
| SCHEMBL695762 | 0.84 | PDK2 (0.39) | LTA4HNR1H2NR1H3PDK2SCN9A | |
| SCHEMBL11391950 | 0.78 | LTA4H (0.53) | LTA4HNR1H2BAXTSHR | |
| SCHEMBL695601 | 0.77 | EPHX2 (0.42) | LTA4HNR1H2NR1H3PDK2TSHR | |
| SCHEMBL2093112 | 0.76 | LTA4H (0.55) | LTA4HNR1H2BAXTSHR | |
| SCHEMBL876364 | 0.75 | LTA4H (0.47) | LTA4HNR1H2NR1H3MAPK14 | |
| SCHEMBL6184207 | 0.75 | LTA4H (0.53) | LTA4HNR1H2BAXTSHR | |
| SCHEMBL20439168 | 0.75 | LTA4H (0.53) | LTA4HNR1H2BAXTSHR | |
| SCHEMBL11255857 | 0.75 | LTA4H (0.53) | LTA4HNR1H2NR1H3BAXTSHR | |
| SCHEMBL28534453 | 0.75 | LTA4H (0.44) | LTA4HNR1H2NR1H3PDK2BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | LTA4H 484/4885NR1H2 1528/4885NR1H3 2115/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | LTA4H 16/4885NR1H2 239/4885NR1H3 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.